We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$209M
AUM Growth
+$36.3M
Cap. Flow
+$35.6M
Cap. Flow %
17.03%
Top 10 Hldgs %
52.12%
Holding
81
New
22
Increased
17
Reduced
10
Closed
28

Top Buys

Rank Stock Value
1
OLED icon
Universal Display
OLED
+$12.7M
2
TVTX icon
Travere Therapeutics
TVTX
+$7.39M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$7.03M
4
CEMP
Cempra, Inc.
CEMP
+$6.54M
5
IMMU
Immunomedics Inc
IMMU
+$6.29M

Top Sells

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$4.3M
2
BEAT
BioTelemetry, Inc.
BEAT
+$3.79M
3
EXEL icon
Exelixis
EXEL
+$3.76M
4
WBMD
WebMD Health Corp.
WBMD
+$3.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.09M

Sector Composition

Rank Sector Weight
1 Healthcare 66.18%
2 Technology 7.48%
3 Consumer Discretionary 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLED icon
1
Universal Display
OLED
$3.67B
$15.6M 7.48%
+287,397
New +$12.7M
IOVA icon
2
Iovance Biotherapeutics
IOVA
$1.93B
$14.8M 7.07%
1,915,000
+600,041
+46% +$4.16M
FOLD
3
DELISTED
Amicus Therapeutics
FOLD
$14.6M 6.97%
1,502,661
+97,994
+7% +$883K
VCYT icon
4
Veracyte
VCYT
$3.58B
$12.4M 5.91%
1,716,000
+811,000
+90% +$5.46M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$12.2M 5.82%
3,964,033
+2,252,966
+132% +$6.29M
ASND icon
6
Ascendis Pharma A/S
ASND
$16B
$9.51M 4.55%
519,243
+49,350
+11% +$865K
NDRM
7
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$8.14M 3.89%
477,300
-19,330
-4% -$377K
CEMP
8
DELISTED
Cempra, Inc.
CEMP
$7.78M 3.72%
250,000
+235,000
+1,567% +$6.54M
TVTX icon
9
Travere Therapeutics
TVTX
$5.11B
$7.14M 3.41%
+370,000
New +$7.39M
SBBP
10
DELISTED
Strongbridge Biopharma plc.
SBBP
$6.87M 3.28%
+978,907
New +$7.03M
EXEL icon
11
Exelixis
EXEL
$13.8B
$6.81M 3.26%
1,207,726
-672,278
-36% -$3.76M
OLED icon
12
CALL
Universal Display
OLED
$3.67B
$6.16M 2.95%
+113,200
New +$4.99M
CYNA
13
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$5.76M 2.75%
376,647
+63,123
+20% +$959K
XBI icon
14
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$5.62M 2.69%
80,000
+10,000
+14% +$682K
QQQ icon
15
PUT
Invesco QQQ Trust
QQQ
$469B
$5.59M 2.68%
+50,000
New +$5.58M
INCY icon
16
Incyte
INCY
$24B
$4.78M 2.29%
+44,078
New +$4.92M
CASM
17
DELISTED
CAS Medical Systems, Inc.
CASM
$4.52M 2.16%
2,551,803
+4,504
+0.2% +$6.36K
RRM
18
DELISTED
RR MEDIA LTD ORD SHS (ISR)
RRM
$4.5M 2.15%
497,227
+27,877
+6% +$244K
IRIX icon
19
IRIDEX
IRIX
$14.4M
$4.25M 2.03%
457,000
+59,804
+15% +$534K
NBRV
20
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.97M 1.9%
1,651
+246
+18% +$600K
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.7B
$3.17M 1.52%
+56,000
New +$2.85M
SRPT icon
22
CALL
Sarepta Therapeutics
SRPT
$1.68B
$2.89M 1.38%
+75,000
New +$2.43M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.79M 1.34%
+88,439
New +$3.12M
INNL
24
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.66M 1.27%
320,555
+46,574
+17% +$466K
ATRA icon
25
Atara Biotherapeutics
ATRA
$77M
$2.51M 1.2%
+3,800
New +$2.87M
1
2 3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q4 2015 Portfolio in Review

As of Q4 2015, Acuta Capital Partners held 81 positions worth $209M, up 21% from $173M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Acuta Capital Partners deployed $35.6M of net new capital in Q4 2015, opening 22 new positions and adding to 17 existing holdings. Its largest new stake was Universal Display: 287,397 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was BioTelemetry, Inc., an estimated $3.79M trimmed.

  • Acuta Capital Partners's largest Q4 2015 buy was Universal Display: 287,397 shares worth $15.6M.
  • Acuta Capital Partners added most to Cempra, Inc. in Q4 2015, an estimated $6.54M increase.
  • Acuta Capital Partners's biggest Q4 2015 reduction was BioTelemetry, Inc., cutting an estimated $3.79M.
  • Acuta Capital Partners fully exited Lexicon Pharmaceuticals in Q4 2015, selling an estimated $4.3M.
  • Acuta Capital Partners's ten largest holdings make up 52% of its $209M portfolio in Q4 2015.
  • Acuta Capital Partners opened 22 new positions and closed 28 in Q4 2015.
  • Acuta Capital Partners's portfolio value rose 21% quarter-over-quarter to $209M.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.